Allogene Therapeutics, Inc.
For the period ended May 12, 2026. Filed May 13, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
May 12, 2026 · Filed May 13, 2026
ALLO$1.04-4.6%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · SELECTED FINANCIAL DATA
SELECTED FINANCIAL DATA
(unaudited; in thousands, except share and per share data)
STATEMENTS OF OPERATIONS
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating expenses: | ||
| Research and development | $32,003 | $50,200 |
| General and administrative | 14,089 | 14,991 |
| Total operating expenses | 46,092 | 65,191 |
| Loss from operations | (46,092) | (65,191) |
| Other income (expenses), net: | ||
| Interest and other income, net | 3,573 | 5,516 |
| Interest expense | (300) | (150) |
| Other income (expenses), net | 212 | 92 |
| Total other income (expenses), net | 3,485 | 5,458 |
| Net loss | $(42,607) | $(59,733) |
| Net loss per share, basic and diluted | $(0.18) | $(0.28) |
| Weighted-average number of shares used in computing net loss per share, basic and diluted | 240,290,782 | 215,358,619 |
SELECTED BALANCE SHEET DATA
| As of March 31, 2026 | As of December 31, 2025 | |
|---|---|---|
| Cash, cash equivalents and investments | $266,886 | $258,253 |
| Total assets | 395,958 | 415,905 |
| Total liabilities | 117,083 | 123,363 |
| Total stockholders’ equity | 278,875 | 292,542 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.